From Financial Modeling Prep: 2024-10-31 03:03:57

In summary, NovoCure (NASDAQ:NVCR) reported an EPS of -$0.28, beating estimates and showing improvement from the previous year. The revenue of approximately $155.1 million exceeded expectations, reflecting growing sales. However, the company faces financial hurdles with a negative P/E ratio of -12.28 and struggles in generating positive operating cash flow. NovoCure’s low debt-to-equity ratio is a positive, but challenges in profitability persist.



Read more at Financial Modeling Prep:: NovoCure (NASDAQ:NVCR) Shows Positive Signs Amid F…